FLT3 and acute myeloid leukemia: While FLT3 inhibitors are now established therapies in combination regimens in FLT3-mutated AML, it is of interest that several non-targeted chemotherapy strategies have also shown selective benefits in FLT3-mutated AML, including induction regimens containing high-dose cytarabine, cladribine and high-dose daunorubicin92,125,126.